Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy males or females~2. Age 18-50 years (incl.)~3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)~4. Subjects must be able to understand and comply with study requirements~Exclusion criteria:~Any deviation from healthy condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- High dose, fasted (Type: EXPERIMENTAL): 1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
- High dose, fed (Type: EXPERIMENTAL): 1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
- Low dose, fasted (Type: EXPERIMENTAL): 2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions

Based on this trial design, predict the completion outcome and termination type (if applicable).